论文部分内容阅读
目的分析乳腺癌患者的临床病理特征及5种免疫组化指标表达情况的关系,探讨其临床意义。方法采用免疫组化SP法对338例乳腺癌患者的术后石蜡标本进行ER、PR、C-erbB-2、Ki-67、P53检测,并对患者临床特征进行分析。结果乳腺癌组织中ER、PR、C-erbB-2的阳性表达率分别为51.75%、34.9%、36.7%。P53和Ki-67的阳性表达率分别为53.8%、91.1%。肿瘤直径≤2cm中ER、PR的阳性表达率最高(61.6%和43%)。P53、ki-67的阳性表达与C-erbB-2的表达呈正相关,P53、Ki-67的阳性表达均与ER阳性表达呈负相关。结论乳腺癌组织中ER、PR、CerbB-2与P53、Ki-67之间有一定的联系,联合检测对乳腺癌诊断、治疗选择和预测预后有重要意义。
Objective To analyze the clinicopathological features and expression of five immunohistochemical markers in patients with breast cancer and to explore its clinical significance. Methods The immunohistochemical SP method was used to detect the postoperative paraffin embedded specimens of 338 cases of breast cancer patients with ER, PR, C-erbB-2, Ki-67 and P53. The clinical characteristics of the patients were analyzed. Results The positive rates of ER, PR and C-erbB-2 in breast cancer tissues were 51.75%, 34.9% and 36.7% respectively. The positive rates of P53 and Ki-67 were 53.8% and 91.1% respectively. The positive expression rate of ER and PR was the highest (61.6% and 43%) in tumor diameter ≤2cm. The positive expressions of P53 and ki-67 were positively correlated with the expression of C-erbB-2. The positive expressions of P53 and Ki-67 were negatively correlated with the positive expression of ER. Conclusion There is a certain relationship between ER, PR, CerbB-2 and P53, Ki-67 in breast cancer. The combined detection is of great significance for the diagnosis, treatment selection and prognosis of breast cancer.